U.S. Drug-Coated Balloons Market Threatened by Reimbursement Cuts and Competitive Pressure

Conclusion Launched in late 2014, DCB sales exploded in 2015, following the establishment of the TPT payment. Rapid growth persisted through 2016 and 2017, fueled by favorable reimbursement, strong clinical results, and new indications for ISR, long lesions, and AV access. The expiration of the TPT payment threatens to cause DCB unit sales and ASPs to contract in 2018. The DCB space is fiercely competitive, and market leaders Medtronic and C. R. Bard are constantly refining their respective DCB portfolios to gain the edge in the high-profile market. Spectranetics threw its hat in the ring in 2017, but is yet to make a substantial impact on the competitive landscape. In the long term, new entrants to the DCB market will ratchet up competitive pressure, fueling further price erosion. For More Information About This Research The information in this article was taken from a global report series entitled Peripheral Vascular Devices Market. Brand and SKU-level pricing data presented in this article is taken from iData’s MedTrack. Resources The Lutonix 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S. for the Treatment of Femoropopliteal Occlusive Disease. C. R. Bard. [Cited 28 Feb 2018.] C. R. Bard Receives FDA Premarket Approval of the LUTONIX® 035 Drug Coated Balloon as the First and Only DCB for the Treatment of Patients with Dysfunctional AV Fistulae. C. R. Bard. [Cited 28 Feb 2018.] US Peripheral Vascular Market Report Suite 2018 - MedSui...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news